Literature DB >> 29674509

Antigen Presentation Keeps Trending in Immunotherapy Resistance.

Anusha Kalbasi1,2,3, Antoni Ribas4,3,5.   

Abstract

Through a gain-of-function kinome screen, MEX3B was identified as a mediator of resistance to T-cell immunotherapy not previously identified using CRISPR-based screens. MEX3B is a posttranscriptional regulator of HLA-A, validating the critical role of tumor-intrinsic antigen presentation in T-cell immunotherapy and indicating a new putative molecular target. Clin Cancer Res; 24(14); 3239-41. ©2018 AACRSee related article by Huang et al., p. 3366. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29674509      PMCID： PMC6050090          DOI： 10.1158/1078-0432.CCR-18-0698

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.

Authors:  Deng Pan; Aya Kobayashi; Peng Jiang; Lucas Ferrari de Andrade; Rong En Tay; Adrienne M Luoma; Daphne Tsoucas; Xintao Qiu; Klothilda Lim; Prakash Rao; Henry W Long; Guo-Cheng Yuan; John Doench; Myles Brown; X Shirley Liu; Kai W Wucherpfennig
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

2.  The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.

Authors:  Lu Huang; Shruti Malu; Jodi A McKenzie; Miles C Andrews; Amjad H Talukder; Trang Tieu; Tatiana Karpinets; Cara Haymaker; Marie-Andrée Forget; Leila J Williams; Zhe Wang; Rina M Mbofung; Zhi-Qiang Wang; Richard Eric Davis; Roger S Lo; Jennifer A Wargo; Michael A Davies; Chantale Bernatchez; Timothy Heffernan; Rodabe N Amaria; Anil Korkut; Weiyi Peng; Jason Roszik; Gregory Lizée; Scott E Woodman; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2018-03-01       Impact factor: 12.531

3.  Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

Authors:  Daniel Sanghoon Shin; Jesse M Zaretsky; Helena Escuin-Ordinas; Angel Garcia-Diaz; Siwen Hu-Lieskovan; Anusha Kalbasi; Catherine S Grasso; Willy Hugo; Salemiz Sandoval; Davis Y Torrejon; Nicolaos Palaskas; Gabriel Abril Rodriguez; Giulia Parisi; Ariel Azhdam; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Beata Berent-Maoz; I Peter Shintaku; Dung T Le; Drew M Pardoll; Luis A Diaz; Paul C Tumeh; Thomas G Graeber; Roger S Lo; Begoña Comin-Anduix; Antoni Ribas
Journal:  Cancer Discov       Date:  2016-11-30       Impact factor: 39.397

4.  Identification of essential genes for cancer immunotherapy.

Authors:  Shashank J Patel; Neville E Sanjana; Rigel J Kishton; Arash Eidizadeh; Suman K Vodnala; Maggie Cam; Jared J Gartner; Li Jia; Seth M Steinberg; Tori N Yamamoto; Anand S Merchant; Gautam U Mehta; Anna Chichura; Ophir Shalem; Eric Tran; Robert Eil; Madhusudhanan Sukumar; Eva Perez Guijarro; Chi-Ping Day; Paul Robbins; Steve Feldman; Glenn Merlino; Feng Zhang; Nicholas P Restifo
Journal:  Nature       Date:  2017-08-07       Impact factor: 49.962

5.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.

Authors:  Robert T Manguso; Hans W Pope; Margaret D Zimmer; Flavian D Brown; Kathleen B Yates; Brian C Miller; Natalie B Collins; Kevin Bi; Martin W LaFleur; Vikram R Juneja; Sarah A Weiss; Jennifer Lo; David E Fisher; Diana Miao; Eliezer Van Allen; David E Root; Arlene H Sharpe; John G Doench; W Nicholas Haining
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962
  5 in total
  3 in total

Review 1.  The Role of the RNA-Binding Protein Family MEX-3 in Tumorigenesis.

Authors:  Simon Jasinski-Bergner; André Steven; Barbara Seliger
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

Review 2.  Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance.

Authors:  Xiaoting Zhou; Yanghong Ni; Xiao Liang; Yi Lin; Biao An; Xiang He; Xia Zhao
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

3.  The future of cancer immunotherapy: microenvironment-targeting combinations.

Authors:  Yonina R Murciano-Goroff; Allison Betof Warner; Jedd D Wolchok
Journal:  Cell Res       Date:  2020-05-28       Impact factor: 25.617
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.